{"id":390646,"date":"2018-06-18T00:00:00","date_gmt":"2018-06-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0047-2018-biopharma-idiopathic-pulmonary-fibrosis-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-18T11:39:23","modified_gmt":"2026-04-18T11:39:23","slug":"algoim0047-2018-biopharma-idiopathic-pulmonary-fibrosis-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0047-2018-biopharma-idiopathic-pulmonary-fibrosis-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>Idiopathic pulmonary fibrosis (<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>) is an orphan disease affecting\u00a0approximately 50,000\u00a0people in the United States. It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality; most patients die within three to five years following diagnosis. Pirfenidone (Roche\u2019s Esbriet) and nintedanib (Boehringer Ingelheim\u2019s Ofev) are the only two drugs\u00a0approved for adults with mild to moderate\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>. Other than these two\u00a0disease-modifying therapies\u00a0(<abbr data-original-title=\"disease-modifying therapy\" title=\"\">DMT<\/abbr>s), physicians also prescribe other\u00a0off-label medications (e.g., corticosteroids and anticoagulants) to treat\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>\u00a0patients when\u00a0the risk\/benefit profile does not warrant treatment with pirfenidone or nintedanib, or when patients cannot receive reimbursement or afford the coinsurance for these two\u00a0<abbr data-original-title=\"disease-modifying therapy\" title=\"\">DMT<\/abbr>s.\u00a0Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of treatment in newly diagnosed\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>\u00a0patients?<\/li>\n<li>What proportion of\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>\u00a0patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with\u00a0<abbr data-original-title=\"idiopathic pulmonary fibrosis\" title=\"\">IPF<\/abbr>\u00a0?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis\u00a0provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390646","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-idiopathic-pulmonary-fibrosis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390646\/revisions"}],"predecessor-version":[{"id":393770,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390646\/revisions\/393770"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}